Results 151 to 160 of about 4,245 (206)

Somatostatin receptor PET-guided treatment and artificial intelligence applications in meningioma: a comprehensive review. [PDF]

Am J Nucl Med Mol Imaging
Gujral J, Gandhi OH, Amanullah AA, Singh SB, Ayubcha C, Werner TJ, Revheim ME, Alavi A.   +7 more
europepmc   +1 more source

¹⁷⁷Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Wang J, Pang X, Lian J, Lu H.
europepmc   +1 more source

Successful management and 10-year survival of a rectal neuroendocrine tumor with rare systemic metastases via a non-portal venous pathway. [PDF]

Clin J Gastroenterol
Horiguchi S, Matsumoto K, Miyamoto K, Matsumi A, Terasawa H, Fujii Y, Takagi K, Kuise T, Tanaka T, Otsuka M.   +9 more
europepmc   +1 more source

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer. [PDF]

Pharmaceutics
Zavvar TS, Santo G, Gruber L, Kronthaler A, Hagenbuchner J, Skvortsova I, Piro I, Steiger K, Martinovic V, Minasch D, Löffler-Ragg J, di Santo G, Virgolini IJ, von Guggenberg E.   +13 more
europepmc   +1 more source

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [¹⁸F]FDG-positive metastatic neuroendocrine tumors. [PDF]

Eur J Nucl Med Mol Imaging
di Santo G, Santo G, Wirth L, Kronthaler A, Gastl G, Djanani A, Virgolini IJ.   +6 more
europepmc   +1 more source

Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)

Endocrine Pathology, 2020
Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic option for pancreatic neuroendocrine tumors (PanNETs). A possible role for PRRT as a neoadjuvant agent is still largely undetermined, explored only in case reports or small case series.
Marco Schiavo Lena, Stefano Partelli, Eleonora Pisa   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15 ...
Jaap J M Teunissen, Boen L R Kam, Wouter W De Herder   +2 more
exaly   +4 more sources

Peptide Receptor Radionuclide Therapy (PRRT)

2016
There has been tremendous progress over recent years on the development of peptide receptor radionuclide therapy (PRRT) for the treatment of a variety of cancers. In this technology, peptides radiolabeled with therapeutic radionuclides are targeted to cell-surface receptors which are often overexpressed on the membrane surface of tumor cells.
F F Knapp, Ashutosh Dash, Knapp F F
exaly   +2 more sources